Relatoks

2022: Start of deliveries to Belarus

March 30, 2022 it became known about the beginning of the supply of Russian Botox to the Belarusian market. We are talking about botulotoxin type A "Relatox," which is produced according to the full cycle at the enterprise of NPO "Microgen" of the holding "Natsimbio" (part of the state corporation "Rostec") in Ufa.

The drug is used in cosmetology, as well as for the treatment of neurological diseases (blepharospasm and limb muscle spasticity after stroke and cerebral palsy). In addition, by the end of March 2022, Microgen is working to expand indications for the use of Relatox in neurology, in particular, clinical studies of the drug are underway as a drug for the therapy of migraine and cervical dystonia.

Russian Botox began to supply to Belarus

{{quote 'Bringing the drug to a new market is always a big event. We hope that with the arrival of the Russian Relatox in Belarus, the availability of botulinotherapy for residents of the republic will increase many times. Shipments have already begun, in total this year we plan to supply about 10 thousand packages, "said Andriy Zagorski, Director General of Natsimbio Holding, whose words are quoted by the Rostec press service. }} According to the executive director of Rostec Oleg Yevtushenko, in addition to Belarus, the first domestic drug for botulinotherapy Relatox was registered in Kyrgyzstan and Uzbekistan. In Russia, by the end of March 2022, more than 1.6 million patients of aesthetic medicine clinics received this remedy.

According to the press service of Rostec, the production of Relatox uses modern filtration, chromatography, lyophilization technologies to ensure its high quality. In cosmetology, the drug is recommended for use on the principle of full face, that is, it aims at general harmonization of the face, and not at eliminating individual wrinkles.^[1]

Notes